Literature DB >> 19352468

Accomplishments in 2007 in the management of localized gastric cancer.

Cornelis J H van de Velde1, Al B Benson.   

Abstract

Overview of the Disease Process IncidencePrognosisCurrent General Therapy Standards SurgeryAdjuvant RadiotherapyAdjuvant ChemotherapyAdjuvant Chemotherapy After D2 DissectionCombined ChemoradiotherapyAccomplishments During the Year TherapyWhat Needs To Be Done (Application of the Accomplishments) Controversies and DisagreementsFuture Directions Comments on Research CRITICS StudyCALGB 80101Obstacles to Progress.

Entities:  

Year:  2008        PMID： 19352468      PMCID： PMC2664909     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN： 1934-7820


  32 in total

1.  The gastric cancer treatment controversy.

Authors:  Cornelis J H van de Velde; Koen C M J Peeters
Journal:  J Clin Oncol       Date:  2003-06-15       Impact factor: 44.544

2.  The debate is over; it's time to move on.

Authors:  Nicholas J Petrelli
Journal:  J Clin Oncol       Date:  2004-04-13       Impact factor: 44.544

3.  Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente).

Authors:  E Mari; I Floriani; A Tinazzi; A Buda; M Belfiglio; M Valentini; S Cascinu; S Barni; R Labianca; V Torri
Journal:  Ann Oncol       Date:  2000-07       Impact factor: 32.976

4.  Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.

Authors:  E Van Cutsem; C Twelves; J Cassidy; D Allman; E Bajetta; M Boyer; R Bugat; M Findlay; S Frings; M Jahn; J McKendrick; B Osterwalder; G Perez-Manga; R Rosso; P Rougier; W H Schmiegel; J F Seitz; P Thompson; J M Vieitez; C Weitzel; P Harper
Journal:  J Clin Oncol       Date:  2001-11-01       Impact factor: 44.544

Review 5.  Chemotherapy for advanced gastric cancer.

Authors:  A D Wagner; W Grothe; S Behl; G Kleber; A Grothey; J Haerting; W E Fleig
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18

6.  Low Maruyama index surgery for gastric cancer: blinded reanalysis of the Dutch D1-D2 trial.

Authors:  K C M J Peeters; S A Hundahl; E Klein Kranenbarg; H Hartgrink; C J H van de Velde
Journal:  World J Surg       Date:  2005-12       Impact factor: 3.352

7.  Validation of a nomogram for predicting disease-specific survival after an R0 resection for gastric carcinoma.

Authors:  Koen C M J Peeters; Michael W Kattan; Henk H Hartgrink; Elma Klein Kranenbarg; Martin S Karpeh; Murray F Brennan; Cornelis J H van de Velde
Journal:  Cancer       Date:  2005-02-15       Impact factor: 6.860

8.  Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma.

Authors:  Michael W Kattan; Martin S Karpeh; Madhu Mazumdar; Murray F Brennan
Journal:  J Clin Oncol       Date:  2003-10-01       Impact factor: 44.544

9.  A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.

Authors:  T R J Evans; G Pentheroudakis; J Paul; A McInnes; R Blackie; N Raby; R Morrison; G M Fullarton; M Soukop; A C McDonald
Journal:  Ann Oncol       Date:  2002-09       Impact factor: 32.976

10.  Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group.

Authors:  A Cuschieri; S Weeden; J Fielding; J Bancewicz; J Craven; V Joypaul; M Sydes; P Fayers
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.